- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03223168
Noninvasive Negative Pressure Ventilation to Support Failing Fontan Physiology
October 4, 2019 updated by: David Peng, University of Michigan
The purpose of this study is to assess for acute hemodynamic changes after implementation of noninvasive negative pressure ventilation (as compared with spontaneous respiration) in pediatric patients with Fontan failure using modern negative pressure ventilators
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
1. Patients with Fontan physiology with clinical evidence of Fontan failure as defined by those with one of the following in addition to Fontan circulation: New York Heart Association Class II, fluid retention, cyanosis, protein losing enteropathy, renal/hepatic dysfunction and/or subjectively qualify for hemodynamic assessment (by primary cardiologist).
Exclusion Criteria:
- Patients which will likely require intubation for catheterization
- Severely depressed systemic ventricular systolic function
- Baseline airway obstruction
- Plastic bronchitis
- Significant OUTFLOW obstruction
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Hayek RTX ventilator
Participants will receive noninvasive negative pressure ventilation.
|
Participants will receive Noninvasive negative pressure from the Hayek RTX ventilator for 30 minutes during diagnostic catheterization procedure.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hemodynamics as characterized by change in pulmonary artery pressure
Time Frame: Baseline, 45 Minutes
|
Pulmonary artery wedge pressure will be measured in millimeters of mercury (mmHg) at baseline and completion of noninvasive negative pressure ventilation.
|
Baseline, 45 Minutes
|
|
Hemodynamics as characterized by change in pulmonary blood flow
Time Frame: Baseline, 45 Minutes
|
Change in pulmonary blood flow will be measured at baseline and completion of noninvasive negative pressure ventilation.
|
Baseline, 45 Minutes
|
|
Hemodynamics as characterized by change in systemic arterial saturation
Time Frame: Baseline, 45 Minutes
|
Systemic arterial saturation measures the amount of oxygen in the blood stream.
Systemic arterial saturation will be registered at baseline and completion of noninvasive negative pressure ventilation.
|
Baseline, 45 Minutes
|
|
Hemodynamics as characterized by change in cardiac output
Time Frame: Baseline, 45 Minutes
|
Cardiac output will be measured in liters per minute at baseline and completion of noninvasive negative pressure ventilation
|
Baseline, 45 Minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: David Peng, MD, University of Michigan
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 19, 2017
Primary Completion (Actual)
June 13, 2018
Study Completion (Actual)
July 19, 2018
Study Registration Dates
First Submitted
July 17, 2017
First Submitted That Met QC Criteria
July 19, 2017
First Posted (Actual)
July 21, 2017
Study Record Updates
Last Update Posted (Actual)
October 7, 2019
Last Update Submitted That Met QC Criteria
October 4, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HUM00131186
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Congenital Heart Disease
-
Paul FinnCompletedPediatric Congenital Heart DiseaseUnited States
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingAdult Congenital Heart Disease | Congenital Heart Disease (CHD) | Pediatric Congenital Heart Disease | Heart Transplant PatientsItaly
-
Cukurova UniversityCompletedPediatric HD | Cyanotic Congenital Heart DiseaseTurkey
-
National Taiwan University HospitalActive, not recruitingCongenital Heart Disease | PediatricTaiwan
-
University of MichiganUniversity of NebraskaCompletedCongenital Heart Disease | Pediatric Congenital Heart Disease | TransitionUnited States
-
KU LeuvenCAS Medical Systems, Inc.CompletedPediatric Congenital Heart SurgeryBelgium
-
Hong Kong Children's HospitalUnknownCardiomyopathies | Cardiac Disease | Congenital Disorders | Pediatric DiseaseHong Kong
-
University of AlbertaCompletedPediatric ALL | Congenital Heart Disease | ERASCanada
-
Deutsches Herzzentrum MuenchenTechnical University of Munich; Stiftung KinderHerz Deutschland gGmbHRecruitingPediatric ALL | Congenital Heart DiseaseGermany
-
The Hospital for Sick ChildrenUniversity Health Network, TorontoNot yet recruitingAcquired Heart Disease | Pulmonary Hypertension | Congenital Heart Disease (CHD) | Post Cardiac Surgery | Pediatric Heart FailureCanada
Clinical Trials on Hayek RTX ventilator
-
University Health Network, TorontoHayek MedicalCompleted
-
Hadassah Medical OrganizationUnknownPneumonia | Chronic Obstructive Pulmonary Disease | Neuromuscular Diseases | Respiratory Insufficiency | Pulmonary EdemaIsrael
-
University Medical Center of Southern NevadaUnknown
-
Emory UniversityLunair MedicalRecruitingObstructive Sleep ApneaUnited States
-
Ray Therapeutics, Inc.Recruiting
-
Ray Therapeutics, Inc.Active, not recruitingRetinitis Pigmentosa | ChoroideremiaUnited States
-
Rubius TherapeuticsTerminatedNon Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Cutaneous Melanoma | TNBC - Triple-Negative Breast CancerUnited States
-
Rubius TherapeuticsTerminated
-
Rubius TherapeuticsTerminatedCervical Cancer | Head and Neck Cancer | Anal CancerUnited States
-
Sorrento Therapeutics, Inc.CompletedIntractable Cancer PainUnited States